913534-05-1 Usage
Uses
Used in Pharmaceutical Industry:
N-Cyclohexyl-7-chloro-1-[2-(4-morpholinyl)ethyl]quinolin-4(1H)-one-3-carboxamide is used as a cannabinoid CB2 receptor agonist for its potential therapeutic applications in various medical conditions. Its high affinity and selectivity for the CB2 receptor make it a promising candidate for the development of targeted drug therapies.
Used in Pain Management:
As a CB2 receptor agonist, N-Cyclohexyl-7-chloro-1-[2-(4-morpholinyl)ethyl]quinolin-4(1H)-one-3-carboxamide may be used for pain management, particularly in chronic pain conditions. The activation of CB2 receptors has been shown to modulate pain signaling pathways, offering a potential non-opioid alternative for pain relief.
Used in Inflammatory Diseases:
N-Cyclohexyl-7-chloro-1-[2-(4-morpholinyl)ethyl]quinolin-4(1H)-one-3-carboxamide may also be used in the treatment of inflammatory diseases due to the role of CB2 receptors in immune system regulation. By targeting CB2 receptors, N-Cyclohexyl-7-chloro-1-[2-(4-morpholinyl)ethyl]quinolin-4(1H)-one-3-carboxamide could potentially help reduce inflammation and alleviate symptoms associated with various inflammatory conditions.
Used in Neurodegenerative Diseases:
Given the involvement of the endocannabinoid system in neuroprotection and the modulation of neuroinflammation, N-Cyclohexyl-7-chloro-1-[2-(4-morpholinyl)ethyl]quinolin-4(1H)-one-3-carboxamide may have potential applications in the treatment of neurodegenerative diseases such as Alzheimer's, Parkinson's, and multiple sclerosis. Its ability to selectively target CB2 receptors could provide a more targeted approach to managing these conditions.
Overall, N-Cyclohexyl-7-chloro-1-[2-(4-morpholinyl)ethyl]quinolin-4(1H)-one-3-carboxamide is a promising compound with potential applications in various medical fields, particularly in the development of targeted therapies for pain management, inflammatory diseases, and neurodegenerative conditions. Its high affinity and selectivity for the CB2 receptor make it a valuable candidate for further research and development in the pharmaceutical industry.
Check Digit Verification of cas no
The CAS Registry Mumber 913534-05-1 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 9,1,3,5,3 and 4 respectively; the second part has 2 digits, 0 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 913534-05:
(8*9)+(7*1)+(6*3)+(5*5)+(4*3)+(3*4)+(2*0)+(1*5)=151
151 % 10 = 1
So 913534-05-1 is a valid CAS Registry Number.
913534-05-1Relevant articles and documents
Design, synthesis, and biological evaluation of new 1,8-naphthyridin-4(1H)- on-3-carboxamide and quinolin-4(1H)-on-3-carboxamide derivatives as CB 2 selective agonists
Manera, Clementina,Benetti, Veronica,Castelli, M. Paola,Cavallini, Tiziana,Lazzarotti, Sara,Pibiri, Fabio,Saccomanni, Giuseppe,Tuccinardi, Tiziano,Vannacci, Alfredo,Martinelli, Adriano,Ferrarini, Pier Luigi
, p. 5947 - 5957 (2007/10/03)
On the basis of docking studies carried out using the recently published cannabinoid receptor models, new 1,8-naphthyridin-4(1H)-on-3-carboxamide and quinolin-4(1H)-on-3-carboxamide derivatives were designed, synthesized, and tested for their affinities toward the cannabinoid CB1 and CB 2 receptors. Compound 10, which presented p-fluorobenzyl and carboxycycloheptylamide substituents bound in the 1 and 3 positions of the 1,8-naphthyiridine-4-one nucleus, showed a high CB2 affinity with a Ki of 1.0 nM. The substitution of the naphthyridine-4-one nucleus with the quinoline-4-one system determined a general increase in CB2 affinity. In particular, the N-cyclohexyl-7-chloro-1-(2-morpholin-4-ylethyl) quinolin-4(1H)-on-3-carboxamide (40) possessed a remarkable affinity, with Ki of 3.3 nM, which was also accompanied by a high selectivity for the CB2 receptor (Ki(CB1/Ki(CB 2) ratio greater than 303). Moreover, the [35S]GTPγ binding assay and functional studies on human basophils indicated that the 1,8-naphthyridin-4(1H)-on-3-carboxamide derivatives behaved as CB1 and CB2 receptor agonists.
